Quirem Medical

Quirem Medical B.V. is a Dutch company focused on developing and commercializing Selective Internal Radiation Therapy (SIRT) microspheres using the radioisotope Holmium-166. Their innovative Holmium-166 platform technology enhances treatment outcomes for unresectable liver cancer by enabling visualization and quantification of microspheres, which aids in patient selection and treatment planning. Quirem Medical provides a complete CE-marked SIRT solution that includes QuiremScout™ (an imaging agent), QuiremSpheres™ (therapeutic microspheres), and Q-Suite™ (dosimetry software) to support personalized interventional oncology treatments. Founded in Deventer, the Netherlands, Quirem Medical became a wholly owned subsidiary of Terumo Corporation in 2020. The company primarily serves hospitals, oncology centers, and interventional radiology departments that specialize in liver cancer treatment, offering a personalized therapeutic approach through radioembolization. Quirem Medical's products are designed to improve treatment accuracy and patient outcomes for those with liver cancer.

• Employees 19
• Founded 2013
• Annual Revenue $7100000